Immunogenicity of Fractional Dose of the HPV Vaccines (NCT05291871)
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (10 items).
Location: University of Washington Virology Research Clinic — Seattle, Washington
Age range: 27 Years to 45 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior immunization with HPV-vaccine (Cervarix, Gardasil-4, Gardasil-9)
- Currently pregnant or breastfeeding
- Immunedeficiency disease/condition or cancer that causes clinically significant immunosuppression
- Known HIV infection
- Chemotherapy (current or within 12 months) or currently taking a medication that causes clinically significant immunosuppression.
- Unstable medical condition (e.g., malignant hypertension, poorly controlled diabetes)
- Known allergy to vaccine components
- Prior history of HPV-associated cancer
- Any medical condition which, in the opinion of the investigator, may compromise the subject's ability to safely complete the study.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- University of Washington Virology Research Clinic — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Infection
- Feasibility of HPV Testing With Mail-delivered Sample Collection Kits — San Francisco, California
- Intradermal, Fractional Dose of HPV Vaccines: — Seattle, Washington
- PCOM2 - The Physician Communication Intervention, Version 2.0 — Aurora, Colorado
- Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer — New Haven, Connecticut
- An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen — Boston, Massachusetts
Explore by condition: All HPV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.